Document Detail

Hepatotoxicity after high-dose methylprednisolone for demyelinating disease.
MedLine Citation:
PMID:  19935411     Owner:  NLM     Status:  MEDLINE    
Liver toxicity, although not mentioned among the possible adverse effects of corticosteroids, has been occasionally reported in literature. We observed 2 cases of hepatotoxicity after a high-dose methylprednisolone treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence. The first patient developed a histologically documented acute hepatitis and recovered after 3 weeks. In the second patient, a mild augmentation of liver enzymes occurred, followed by normalization in a few days. The causal relationship between hepatotoxicity and methylprednisolone treatment was deemed probable in both cases. Careful review of the literature suggests that corticosteroid-induced liver damage may be more frequent than commonly believed.
Anna Loraschi; Paola Banfi; Marco Mauri; Fausto Sessa; Giorgio Bono; Marco Cosentino
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  33     ISSN:  1537-162X     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-04-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  52-4     Citation Subset:  IM    
Section of Experimental and Clinical Pharmacology, Department of Clinical Medicine, Varese, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Inflammatory Agents / adverse effects*,  therapeutic use*
Demyelinating Diseases / drug therapy
Drug Toxicity / chemically induced
Drug-Induced Liver Injury / etiology*
Methylprednisolone / adverse effects*,  therapeutic use*
Reg. No./Substance:
0/Anti-Inflammatory Agents; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early Addition of Selegiline to L-Dopa Treatment is Beneficial for Patients With Parkinson Disease.
Next Document:  Influenza A pandemics: Clinical and organizational aspects: The experience in Chile.